For your male patients with overactive bladder (OAB)
New Indication:
Gemtesa is the first and only treatment for oab in men treated for BENIGN PROSTATIC HYPERPLASIA (BPH)1,2
More men may be suffering from OAB than you think3,5
As many as
3out of4
men with BPH also have OAB symptoms
Many men still experience OAB symptoms while on treatment for BPH3-5
Meet Carl*
*Not an actual patient.
Questions whether his BPH treatment is enough to relieve his OAB symptoms
Carl was tired of interruptions from his urinary symptoms. When urgency continued despite BPH treatment, he knew he needed to talk to his doctor about how he was feeling.
Do you see patients like Carl in your practice? GEMTESA may help.
Proven safety profile:
Adverse Reactions, Exceeding Placebo Rate, Reported in ≥2% of Patients Treated with GEMTESA 75 mg for up to 12 Weeks1
* Defined as an average systolic blood pressure (SBP) ≥140mmHg or diastolic BP (DBP) ≥90mmHg on 3 assessments at two consecutive visits, in non-hypertensive patients.
* Defined as an average increase of SBP ≥20mmHg or DBP ≥10mmHg on 3 assessments at two consecutive visits, or the initiation or increase in dose of antihypertensive medications at any visit, in hypertensive patients.
The ONLY β3 treatment with NO blood pressure warning in its label1,2,6,7
No CYP2D6† drug interactions1
† Digoxin drug interaction was identified with GEMTESA. Measure serum digoxin concentrations before initiating GEMTESA. Monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect. Continue monitoring digoxin concentrations upon discontinuation of GEMTESA and adjust digoxin dose as needed.1
Proven reduction data for all key symptoms of OAB in its label1,8,9:
Urgency1,6
Frequency1,10
Urge urinary incontinence1,6
Three areas to cover when initially evaluating a patient with symptoms suggestive of OAB11:
1
2
3
Obtain
a medical history with comprehensive assessment of bladder symptoms,
Conduct
a physical examination, and
Perform
a urinalysis to exclude microhematuria and infection